Drug recall · November 14, 2018
Contrave recall
Why: Container packaging defect.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99
- Lots / codes
Lot #: ZYCY, Exp. 04/11/2021
- Quantity
- 18,895 bottles
- Company
- Orexigen Therapeutics, Inc., La Jolla, CA
- Distribution
- Within the United States
- Initiated
- October 5, 2018 · Voluntary: Firm initiated
- Classified
- November 6, 2018
- Reported
- November 14, 2018
- Ended
- November 15, 2019
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupropion
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.